6月9日 - ** 生物技术公司Shattuck Labs STTK.O 股价在盘后交易中下跌4.2%，至4.09美元，此前该公司发布了股票发行消息
** 专注于炎症及免疫介导性疾病的公司已启动 (link) 股票及预先融资认股权证的发行；交易规模未披露
** 联席簿记管理人为Leerink Partners、摩根大通、Piper Sandler及Cantor Fitzgerald
** STTK股价周二上涨9.5%，收于4.27美元，年内累计涨幅达17%
** 这家总部位于得克萨斯州奥斯汀的公司流通股约为7670万股，市值约3.3亿美元
** 据LSEG数据显示，8位分析师均对该股持乐观态度，其中2位给予“强烈买入”评级；目标价中位数为17美元
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.